After a successful start, the group is breaking major news. Following lengthy and demanding preparation and negotiations, we can announce that clinical trials will be conducted on the premises of the Váš Lekár polyclinic in cooperation with an international pharmaceutical company. This is a milestone that significantly improves the project’s profitability profile – it brings a new, high-margin and stable source of revenue, strengthens the polyclinic's prestige and increases its attractiveness to both patients and partners.

What did you learn during the webinar?

• Update in accordance with the new KIIS regulatory document and investment information
• Information on the prestigious inclusion of the Váš Lekár polyclinic in clinical trials by a global pharmaceutical corporation
• Management measures to increase revenue and reduce costs
• Financial results and growth of the group
• Management outlook and vision
• Investor questions and answers

The webinar was led by partners Michal Nešpor, Dano Gašpar, and Peter Potúček, CEO of Váš Lekár.